This work is licensed under a Creative Commons Attribution 4.0 International License.
LTX-302
General Information
DRACP ID DRACP00281
Peptide Name LTX-302
Sequence WKKWXKKWK
Sequence Length 9
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP Membrane lysis
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| HT-29 | Colon adenocarcinoma | Carcinoma | IC50=75 ± 5 µM | MTT assay | 30 min | 1 |
| MT-1 | Human mammary carcinoma | Carcinoma | IC50=73 ± 2 µM | MTT assay | 30 min | 1 |
| Kelly | Neuroblastoma | Blastoma | IC50=28 ± 0 µM | MTT assay | 30 min | 1 |
| A20 | Murine B cell lymphoma | Lymphoma | IC50=16.0 ± 3.0 µM | MTT assay | 4 h | 2 |
| AT84 | Murine squamous cell carcinoma | Carcinoma | IC50=21.0 ± 1.7 µM | MTT assay | 4 h | 2 |
| HL-60 | Adult acute myeloid leukemia; Acute myeloid leukemia | Leukemia | IC50=8.0 ± 1.1 µM | MTT assay | 4 h | 2 |
| HL-60/ADR | Adult acute myeloid leukemia; Acute myeloid leukemia | Leukemia | IC50=10.5 ± 3.1 µM | MTT assay | 4 h | 2 |
| MCF-7 | Invasive breast carcinoma of no special type | Carcinoma | IC50=8.9 ± 2.8 µM | MTT assay | 4 h | 2 |
| MCF-7/mdr | Invasive breast carcinoma of no special type | Carcinoma | IC50=11.0 ± 4.4 µM | MTT assay | 4 h | 2 |
| IGROV-1 | Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary | Carcinoma | IC50=19.6 ± 8.7 µM | MTT assay | 4 h | 2 |
| IGROV-1/CDDP | Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary | Carcinoma | IC50=6.4 ± 2.6 µM | MTT assay | 4 h | 2 |
| K562 | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia | Leukemia | IC50=8.2 ± 1.3 µM | MTT assay | 4 h | 2 |
| K562/Gleevec | Blast phase chronic myelogenous leukemia, BCR-ABL6 positive; Chronic myeloid leukemia | Leukemia | IC50=9.0 ± 2.1 µM | MTT assay | 4 h | 2 |
Hemolytic Activity Human red blood cells (RBC): IC50>695 μM
Normal (non-cancerous) Cytotoxicity HUVEC: IC50=123 ± 9 μM; MRC-5: IC50=122 ± 16 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antimicrobial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification X=Dip (Diphenylalanine)
Chiral L
Physicochemical Information
Formula C63H90N16O8
Absent amino acids ACDEFGHILMNPQRSTVY
Common amino acids K
Mass 145238
Pl 11.4
Basic residues 5
Acidic residues 0
Hydrophobic residues 3
Net charge 5
Boman Index -2076
Hydrophobicity -246.67
Aliphatic Index 0
Half Life
/
Extinction Coefficient cystines 16500
Absorbance 280nm 2062.5
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 21453492
Title Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells
Year 2011
Literature 2
Pubmed ID 26982623
Title Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide
Doi 10.1021/acs.jmedchem.5b02025
Year 2016
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID DBAASPS_11907
This work is licensed under a Creative Commons Attribution 4.0 International License.